With the normalization of China's collection and medical insurance, many pharmaceutical companies have also been challenged by innovation, technology and marketing
.
Among them, many pharmaceutical companies have begun to actively adjust their business
in order to cope with challenges.
In this context, the demand for professionals has also become more urgent
.
Under the acceleration of the development of the pharmaceutical industry, enterprises are accelerating to make up for the shortage of talents (Source: Pharmaceutical Network)
It is understood that local biotech has been thirsty for talents with rich experience, and in recent years, many multinational pharmaceutical company talents have flowed into local pharmaceutical companies
.
For example, in September 2021, AstraZeneca formerly East RGM Zhang Anwei joined Luoxin Group; In January 2022, Yin Min, former General Manager of AstraZeneca's Oncology Division, joined BeiGene as CCO in Greater China.
Zhu Jingyan, former head of the lymphoma business department of Janssen HIPO business unit, joined BeiGene as the head of the hematology and oncology business unit.
.
.
In addition to the increasingly frequent flow of talents, in order to make up for the shortcomings of talents, many pharmaceutical companies are also vigorously expanding talent reserves
.
According to industry statistics, as of April 6, the number of employees of 6 CXO head companies has increased, with a cumulative increase of 18,000 people
.
Among them, WuXi AppTec added 8501 employees, with 6899 R&D personnel, and BeiGene added 2822 new R&D personnel in 2021, accounting for 96%
of the annual R&D personnel.
In addition, in 2021, the number of R&D personnel of Hengrui Pharmaceutical also increased by 16%.
It is worth noting that among the many talents at present, Chinese medicine talents are undoubtedly a category
that has received more attention and training from the country and the pharmaceutical industry.
It is reported that with the help of national policies, Yunnan Province, Heilongjiang Province, Jiangxi Province, Hunan Province and other places have issued documents clearly indicating that they will vigorously develop the traditional Chinese medicine industry, which also mentions the need to consolidate the talent base of
traditional Chinese medicine.
For example, Henan Province proposed in the "14th Five-Year Plan" of Chinese Medicine Development Plan that Henan will continue to improve the education level of traditional Chinese medicine colleges and universities, optimize the talent training model, and cultivate more outstanding talents
in traditional Chinese medicine.
It is necessary to expand the scale of postgraduate training in traditional Chinese medicine and traditional Chinese medicine, increase the proportion of classic courses in traditional Chinese medicine majors in traditional Chinese medicine colleges and universities, and carry out the examination of classical ability level of traditional Chinese medicine.
.
.
Guangxi issued the "Several Policies and Measures on Accelerating the Development of the Characteristics of Traditional Chinese Medicine Zhuangyao Medicine", which also mentioned the need to consolidate the talent base of
Zhuangyao Medicine in Traditional Chinese Medicine.
It will mainly start from the three aspects of improving the level of education, promoting teacher education, improving the talent evaluation and incentive mechanism, and establishing a long-term incentive mechanism for Chinese medicine talents such as Guipai Chinese medicine masters and Guangxi famous Chinese medicine practitioners
.
On the whole, talent has become the source of enterprise innovation, as well as the core elements of enterprise innovation, especially the research and development and production of high-tech products rely on professional talents
to a greater extent.
Therefore, at present, in addition to pharmaceutical companies, pharmaceutical machinery companies are actually accelerating the construction of high-quality scientific and technological personnel and creating hard power
.
At present, according to the author's understanding, many head pharmaceutical machine companies have actively taken action
to expand talent recruitment.
For example, Chutian Technology's 2022 semi-annual report shows that the number of technical research and development personnel in the first half of the year increased by more than 650 people compared with the same period, and the introduction of technical backbone talents is the focus, and shows obvious results, and the number of technical research and development personnel of the group during the reporting period is nearly 2,000
.
In addition, Dongfulong also mentioned in the interim report that the company increased its research and development personnel in the first half of the
year.
From 2020 to 2021, the number of R&D personnel of Dongfulong increased from 396 (accounting for 14.
88%) to 677 (18.
44%)
.
In fact, whether it is a pharmaceutical enterprise or a pharmaceutical machine enterprise, research and development is an important part of it, and having certain research and development capabilities means that the enterprise has core competitiveness and can achieve rapid development
.
However, R&D is also a long-term and continuous process, which requires the support of the talent team, especially the participation
of experienced talents.
Therefore, as pharmaceutical companies and pharmaceutical machinery companies accelerate the development of new products, the industry expects that the demand for related research and development talents will continue to rise
.
